Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. raised its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 152,783 shares of the biopharmaceutical company’s stock after acquiring an additional 4,427 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Royalty Pharma were worth $3,902,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Swedbank AB increased its position in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after buying an additional 1,136,800 shares in the last quarter. State Street Corp increased its position in shares of Royalty Pharma by 0.3% in the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after buying an additional 29,451 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after buying an additional 417,490 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after buying an additional 936,900 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Royalty Pharma by 58.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after buying an additional 1,103,341 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.8 %

Royalty Pharma stock opened at $32.59 on Thursday. The stock has a market cap of $19.20 billion, a PE ratio of 22.48, a P/E/G ratio of 2.24 and a beta of 0.49. The stock has a 50-day moving average price of $28.85 and a 200 day moving average price of $27.85. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $32.92. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.70%. Royalty Pharma’s payout ratio is 57.93%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of research analyst reports. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Citigroup dropped their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.